Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19676690 | 0.81 | SMN1; SMN2 (0.38) | RAB9ASMN1; SMN2CA12CA1CA9 | |
| SCHEMBL17228557 | 0.76 | ALDH1A1 (0.43) | RAB9ASMN1; SMN2CA12CA1CA9 | |
| SCHEMBL5971035 | 0.74 | KDM4E (0.47) | RAB9ASMN1; SMN2CA12CA1CA9 | |
| SCHEMBL13212895 | 0.74 | LMNA (0.62) | RAB9ASMN1; SMN2CA12CA1CA9 | |
| SCHEMBL20930121 | 0.73 | TSHR (0.56) | RAB9ASMN1; SMN2LMNAKMT2AKDM4E | |
| SCHEMBL27574038 | 0.73 | SMN1; SMN2 (0.48) | RAB9ASMN1; SMN2CA12CA1CA9 | |
| SCHEMBL14902310 | 0.72 | HTT (0.46) | RAB9ASMN1; SMN2CA12CA1CA9 | |
| SCHEMBL14902296 | 0.72 | SMN1; SMN2 (0.44) | RAB9ASMN1; SMN2CA12CA1CA9 | |
| Acrylamide SCHEMBL7045841 | 0.71 | MEN1 (0.45) | RAB9ASMN1; SMN2CA12CA1CA9 | |
| SCHEMBL1896875 | 0.70 | RAB9A (0.52) | RAB9ASMN1; SMN2CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452152-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-20150313864-A1 | Fe(III) Complex Compounds for the Treatment and Prophylaxis of Iron Deficiency Symptoms and Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313864-A1 | Fe(III) Complex Compounds for the Treatment and Prophylaxis of Iron Deficiency Symptoms and Iron Deficiency Anemias | FECH, SDHB, SLC40A1 | RAB9A 2451/4885SMN1; SMN2 3363/4885CA12 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.